Edition:
India

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

0.67USD
11:05pm IST
Change (% chg)

$-0.00 (-0.36%)
Prev Close
$0.67
Open
$0.68
Day's High
$0.68
Day's Low
$0.65
Volume
12,193
Avg. Vol
43,574
52-wk High
$3.38
52-wk Low
$0.60

Chart for

About

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally... (more)

Overall

Beta: 3.04
Market Cap(Mil.): $39.03
Shares Outstanding(Mil.): 30.25
Dividend: --
Yield (%): --

Financials

BRIEF-Biocept reports Q3 loss per share $0.20

* Biocept Inc - ‍cash and cash equivalents were $5.9 million as of September 30, 2017​ Source text for Eikon: Further company coverage:

10 Nov 2017

BRIEF-Biocept and Miraca Life Sciences enter into marketing agreement

* Biocept and Miraca Life Sciences enter into marketing agreement to expand target selector testing in the United States

03 Oct 2017

BRIEF-Biocept Inc files for disposition of up to 2.9 million shares of common stock

* Biocept Inc files for disposition of up to 2.9 million shares of common stock by the selling stockholders Source text: (http://bit.ly/2fShoIH) Further company coverage:

19 Aug 2017

BRIEF-Biocept, UT Southwestern Medical Center announce clinical study to profile, monitor non-small cell lung cancer patients

* Biocept and UT Southwestern medical center announce clinical study to profile and monitor non-small cell lung cancer patients with ALK rearrangements Source text for Eikon: Further company coverage:

17 Aug 2017

BRIEF-Biocept enters into distribution agreement with Global Laboratory Product Supplier VWR

* Biocept enters into exclusive distribution agreement with Global Laboratory Product Supplier VWR

14 Aug 2017

BRIEF-Biocept Q2 loss per share $0.21

* Says ‍revenues for Q2 of 2017 increased 93% to $1.3 million​

11 Aug 2017

BRIEF-Biocept announces private placement of $2.2 mln of common stock

* Biocept announces private placement of $2.2 million of common stock with Ally Bridge LB Healthcare Master Fund

10 Aug 2017

BRIEF-Biocept executes preferred provider agreement with Scripps Health Plan

* Biocept executes preferred provider agreement with Scripps Health Plan expanding patient coverage for its liquid biopsy platform Source text for Eikon: Further company coverage:

07 Aug 2017

BRIEF-Biocept launches liquid biopsy test for progesterone receptor detection

* Biocept expands commercial offering of clinically actionable biomarker assays with launch of liquid biopsy test for progesterone receptor detection

14 Jul 2017

BRIEF-Biocept, MediNcrease Health Plans announce provider agreement

* Biocept and medincrease health plans announce provider agreement expanding access to liquid biopsy testing Source text for Eikon: Further company coverage:

21 Jun 2017

Earnings vs. Estimates